Table 3.
Secondary Maternal Outcomes.*
| Outcome | Vitamins (N = 4993) | Placebo (N = 4976) | Relative Risk (95% CI) | P Value |
|---|---|---|---|---|
| Preeclampsia — no. (%) | 358 (7.2) | 332 (6.7) | 1.07 (0.93–1.24) | 0.33 |
| Mild | 212 (4.2) | 191 (3.8) | ||
| Severe | 134 (2.7) | 129 (2.6) | ||
| HELLP syndrome | 2 (<0.1) | 8 (0.2) | ||
| Eclampsia | 10 (0.2) | 4 (0.1) | ||
| Pregnancy-associated hypertension — no. (%) | 1457 (29.2) | 1322 (26.6) | 1.10 (1.03–1.17) | 0.004 |
| Medically indicated delivery because of hypertension — no./total no. (%) | 509/4952 (10.3) | 473/4934 (9.6) | 1.07 (0.95–1.21) | 0.25 |
| Aspartate aminotransferase ≥100 U/liter — no. (%) | 35 (0.7) | 48 (1.0) | 0.73 (0.47–1.12) | 0.15 |
| Creatinine ≥1.5 mg/dl (133 μmol/liter) — no. (%) | 9 (0.2) | 12 (0.2) | 0.75 (0.32–1.77) | 0.51 |
| Antepartum bleeding — no./total no. (%) | 56/4956 (1.1) | 46/4937 (0.9) | 1.21 (0.82–1.79) | 0.33 |
| Premature rupture of membranes — no./total no. (%) | 124/4934 (2.5) | 129/4923 (2.6) | 0.96 (0.75–1.22) | 0.74 |
| Placental abruption — no./total no. (%) | 24/4957 (0.5) | 36/4938 (0.7) | 0.66 (0.40–1.11) | 0.12 |
| Cesarean delivery — no./total no. (%) | 1269/4958 (25.6) | 1224/4940 (24.8) | 1.03 (0.97–1.11) | 0.35 |
| Maternal death — no. (%) | 1 (<0.1) | 1 (<0.1) | — | — |
| Postpartum pulmonary edema — no./total no. (%) | 3/4951 (0.1) | 10/4926 (0.2) | 0.30 (0.08–1.08) | 0.05 |
| Hematocrit ≤24% with transfusion — no./total no. (%) | 40/4954 (0.8) | 59/4927 (1.2) | 0.67 (0.45–1.01) | 0.05 |
| Hospital stay — days | 0.65 | |||
| Median | 2.0 | 2.0 | ||
| Interquartile range | 2.0–3.0 | 2.0–3.0 |
*
HELLP denotes hemolytic anemia, elevated liver enzymes, and low platelet count.